Heidi L. Weiss

Heidi L. Weiss

Auto-generated profile, based on publicly available information

Heidi L. Weiss

Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2001 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
MGMark D. Gibbons
Mark D. Gibbons
CYClayton Yates
Clayton Yates
WCWilliam R. Carroll
William R. Carroll
GPGlenn E. Peters
Glenn E. Peters
HWHeidi L. Weiss
Heidi L. Weiss
WGWilliam E. Grizzle
William E. Grizzle

1 January 2004 in Disease Markers
Verified
Journal Article
Open access
PDF file
HWHeidi L. Weiss
Heidi L. Weiss
SNSantosh Niwas
Santosh Niwas
WGWilliam E. Grizzle
William E. Grizzle
CPChandrika Piyathilake
Chandrika Piyathilake
The role of biomarkers in disease prognosis continues to be an important investigation in many cancer studies. In order for these biomarkers to have practical application in clinical decision making regarding patient treatment and follow-up, it is common to dichotomize patients into those with low vs. high expression levels. In this study, receiver operating characteristic (ROC) curves, area under the curve (AUC) of the ROC, sensitivity, specificity, as well as likelihood ratios were calculated to determine levels of growth factor biomarkers that best differentiate lung cancer cases versus control subjects. Selected cut-off points for p185erbB-2 and EGFR membrane appear to have good discriminating power to differentiate control tissues versus uninvolved tissues from patients with lung cancer (AUC = 89% and 90%, respectively); while AUC increased to at least 90% for selected cut-off points for p185erbB-2 membrane, EGFR membrane, and FASE when comparing between control versus carcinoma tissues from lung cancer cases. Using data from control subjects compared to patients with lung cancer, we presented a simple and intuitive approach to determine dichotomized levels of biomarkers and validated the value of these biomarkers as surrogate endpoints for cancer outcome.